G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case–control study
Elias Jabbour,Michael S. Mathisen,Guillermo Garcia-Manero,Richard E. Champlin,Uday R. Popat,Issa F. Khouri,Sergio Giralt,Tapan M. Kadia,Julianne Chen,Sherry Pierce,Ebru Koca,Naval Daver,Maria Tanaka,Gabriela Rondon,Betul Oran,Simrit Parmar,Hagop M. Kantarjian,Marcos de Lima +17 more
TL;DR: It is suggested that prospective studies are needed to delineate the timing and efficacy of allo‐SCT in the HMA era and to improve survival in patients with high‐risk MDS.
Journal ArticleDOI
Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naïve higher-risk myelodysplastic syndromes.
Amer M. Zeidan,Jacqueline S. Garcia,Pierre Fenaux,Uwe Platzbecker,Yasushi Miyazaki,Zhijian Xiao,Ying Zhou,Kiran Naqvi,Steve Kye,Guillermo Garcia-Manero +9 more
TL;DR: The VERONA study, a randomized, double-blind, phase 3 study of patients with treatment-naïve HR-MDS, will assess the safety and efficacy of Ven combined with Aza including CR rate and overall survival.
Journal ArticleDOI
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study
Shyamala C. Navada,Guillermo Garcia-Manero,Rosalie Odchimar-Reissig,Naveen Pemmaraju,Yesid Alvarado,Maro Ohanian,Rosmy B. John,Erin P. Demakos,Patrick S. Zbyszewski,Manoj Maniar,Richard C. Woodman,Steven M. Fruchtman,Lewis R. Silverman +12 more
TL;DR: In this paper, a Phase 1/2 study comprised 18 patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) who were either hypomethylating agent naive (n = 10) or relapsed/refractory following prior hypomethemylating agents therapy (n= 8) (NCT01926587).
Journal ArticleDOI
Improved Outcomes Among Newly Diagnosed Patients with FLT3-ITD Mutated AML Treated with Contemporary Therapy: Revisiting the ELN Adverse Risk Classification.
Patrick K. Reville,Koji Sasaki,Hagop M. Kantarjian,Naval Daver,Musa Yilmaz,Courtney D. DiNardo,Nicholas J. Short,Gautam Borthakur,Naveen Pemmaraju,Rohtesh S. Mehta,Sherry Pierce,Sergej Konoplev,Joseph D. Khoury,Guillermo Garcia-Manero,Marina Konopleva,Elias Jabbour,Farhad Ravandi,Tapan M. Kadia +17 more
TL;DR: It is shown that FLT3-ITD high allelic ratio with NPM1 wild-type have significantly improved survival compared with other European LeukemiaNet (ELN) adverse risk disease.
Journal ArticleDOI
Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome.
Francesco Paolo Tambaro,Guillermo Garcia-Manero,Susan O'Brien,Stefan Faderl,Alessandra Ferrajoli,Jan A. Burger,Sherry Pierce,Xuemei Wang,Kim Anh Do,Hagop M. Kantarjian,Michael J. Keating,William G. Wierda +11 more
TL;DR: Outcomes for patients with CLL subsequently diagnosed with AL or MDS were very poor; AL/MDS occurred without prior CLL treatment; shorter survival from MDS correlated with higher risk IPSS, poor-risk karyotype and increased number of prior C LL treatments.